Abstract

Objective: A number of encouraging research studies have shown the importance of nutritional approach in order to protect the brainhealth. Here we present the efficacy of a daily administration of a unique complex combination of omega 3 fatty acids and antioxidants (cogniXtra) as a neuroprotective treatment on early symptoms of Alzheimer’s disease (AD) mouse model.
Methods: Mice were treated per os once a day with various combinations of dacosahexaenoic acid (DHA), glutathione (GSH), phosphatidylcholine (PC), curcumin (CUR) and resveratrol (RES) including the special combination cogniXtra (GSH + PC+ CUR + RES + DHA) starting 20 days before and until10 days after the onset of the neurotoxicity induced by a central injection of amyloid-beta 25-35 (Aβ_25-35)- oligomeric peptide. Protection against the neurotoxicity of Aβ_25-35 was assessed carrying out two behavior tests evaluating short-term memory (Y-maze) and long term memory (step through passive avoidance test-STPA) and the measurement of a key brain biomarker, lipid peroxidation (LPO).
Results: Our present research demonstrates the importance of a correct association of different substances whereas the treatment with each of them alone was unable to provide any protection from the toxic effects produced by Aβ_25-35 injection. CogniXtra formulation combining all of the components was the only one able to fully reverse all the memory deficits both in the Y-maze and in the STPA tests and also to completely protect from oxidative stress as demonstrated by the important LPO elevation measured in the hippocampus.
Conclusion: This study indicates that acombination treatment (cogniXtra) administration for thirty consecutive days produces a complete neuroprotective effect on the neurotoxic events produced by Aβ_25-35 oligomeric peptide injection. The efficacy of a preventive treatment with cogniXtrain this preclinical model is similar to what could be achieved with other pharmacological approaches. These results strongly suggest the therapeutic interest of cogniXtra for the preventive treatment of AD.